CRLBF Cresco Labs Inc. Annual reports only
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1832928 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-9.5%
TTM net income YoY-81.9%
TTM EPS YoY-72.7%
Revenue 3-yr CAGR-8.0%
Net income 3-yr CAGR—
Margins
Gross margin49.5%
Operating margin-4.3%
Net margin-20.6%
FCF margin5.8%
EBITDA margin3.2%
Returns
ROE-33.2%
ROA-10.6%
ROIC (approx.)-2.9%
Asset turnover0.51x
Leverage & solvency
Liabilities / assets78.9%
Debt / equity1.23x
Current ratio2.59x
Interest coverage-0.67x
Cash quality & payout
Operating cash flow / net income-0.54x
Accruals ratio-16.3%
Payout ratio—
Capex / revenue5.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $655.85M | $724.34M |
| Cost of revenue | $331.28M | $359.89M |
| Gross profit | $324.57M | $364.45M |
| SG&A expense | $247.45M | $254.84M |
| Operating income | -$27.99M | $107.29M |
| Interest expense | $41.75M | $37.93M |
| Pretax income | -$95.42M | -$10.62M |
| Income tax | $44.62M | $49.87M |
| Net income | -$135.41M | -$74.44M |
| EBITDA | $20.73M | $166.39M |
| EPS (basic) | -0.38 | -0.22 |
| EPS (diluted) | -0.38 | -0.22 |
| Weighted avg. shares (diluted) | 355.01M | 345.47M |
| Balance sheet | ||
| Cash & equivalents | $57.90M | $137.56M |
| Receivables | $37.89M | $51.56M |
| Inventory | $98.67M | $83.34M |
| Current assets | $259.27M | $294.26M |
| PP&E, net | $327.19M | $344.85M |
| Goodwill | $208.17M | $283.48M |
| Intangibles | $275.34M | $293.99M |
| Total assets | $1.20B | $1.36B |
| Current liabilities | $100.18M | $94.34M |
| Short-term debt | $3.30M | $2.61M |
| Long-term debt | $417.10M | $460.75M |
| Total debt | $420.39M | $463.36M |
| Total liabilities | $944.80M | $967.18M |
| Shareholders' equity | $340.45M | $474.85M |
| Net debt | $362.49M | $325.80M |
| Cash flow statement | ||
| Operating cash flow | $72.89M | $132.48M |
| Capital expenditure | $35.14M | $19.49M |
| Free cash flow | $37.75M | $112.99M |
| Investing cash flow | -$40.70M | -$25.23M |
| Financing cash flow | -$82.09M | -$71.48M |
| Depreciation & amortization | $48.71M | $59.10M |
| Stock-based compensation | $11.23M | $14.16M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.